- Home
- IMNN vs GXAI Comparison
IMNN vs GXAI Comparison
Compare IMNN & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNN | GXAI |
|---|---|---|
| Founded | 1982 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 9.1M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | IMNN | GXAI |
|---|---|---|
| Price | $2.99 | $1.39 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $182.61 | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 11.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.00 | ★ 52.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,027.00 |
| Revenue This Year | N/A | $42,959.35 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1473.05 |
| 52 Week Low | $0.37 | $1.00 |
| 52 Week High | $9.32 | $2.96 |
Technical Indicators
Market Signals| Indicator | IMNN | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 51.20 |
| Support Level | $3.03 | $1.11 |
| Resistance Level | $3.16 | $1.39 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 23.73 | 23.72 |
Price Performance
Historical ComparisonAbout IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.